From PvP Biologics Raises $35M in a Lab-to-Pharma Deal with Takeda:

KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)

KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)—

Computer-generated image of KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
How Healthy Are Your Market Access Programs?
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting

Sponsored · Video
The Bay Area and Beyond: Biocom Talks Innovation and COVID
A Fireside Chat with Biocom President & CEO Joe Panetta
Biocom

Sponsored · Webinar
Sept. 15 – Challenges of Implementing Innovation in Drug Discovery & Development
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery

Xconomy on Demand

We offer a number of ways to subscribe for free!